Survival Benefit of ARSI Therapy in Japanese mCSPC : A Systematic Review and Meta‐Analysis
International Journal of Urology · 2026-08 · 33 (8)
DOI: 10.1111/iju.70603 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Urology, online erschienen am 15.08.2026. Verfasst von Hiroaki Iwamoto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists, Androgen Antagonists, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
Randomized clinical trials have shown that second‐generation androgen receptor signaling inhibitors (ARSIs) improve overall survival (OS) in metastatic castration‐sensitive prostate cancer (mCSPC). In Japan, combined androgen blockade (CAB) has been widely used as conventional hormonal therapy, unlike Western trials in which androgen deprivation therapy (ADT) alone was the primary comparator. Whether this treatment context influences the survival benefit of ARSI‐based therapy in Japanese clinical practice remains uncertain.
Methods
We conducted a systematic review and meta‐analysis of studies evaluating ARSI plus ADT versus conventional hormonal therapy (ADT alone or CAB) in Japanese patients with mCSPC. PubMed and Ichushi‐Web were searched through February 2026. Adjusted hazard ratios from multivariable or propensity score–matched analyses were pooled using a random‐effects model. Risk of bias was assessed using ROBINS‐I.
Results
Fourteen studies were included. Eleven all‐comer mCSPC cohorts were included in the primary analysis. ARSI‐based therapy was associated with improved OS compared with conventional hormonal therapy (pooled hazard ratio 0.86, 95% confidence interval 0.77–0.96), with no heterogeneity ( I 2 = 0%). The prediction interval was 0.76 to 0.98. Sensitivity and subgroup analyses, including CAB‐based comparator cohorts, showed consistent results.
Conclusions
ARSI‐based therapy was associated with a modest but consistent improvement in OS in Japanese mCSPC. The attenuated effect size compared with randomized trials may reflect multiple factors, including differences in baseline treatment strategies, subsequent therapies, healthcare systems, and study design. These findings highlight the importance of treatment context when interpreting randomized trial evidence. Trial Registration This systematic review and meta‐analysis was conducted in accordance with the PRISMA 2020 statement and was registered in PROSPERO (registration number: CRD420261380244)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
- Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan.
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
ORCID-Profile: Hiroaki Iwamoto, Kouji Izumi, Tomohiro Hori, Takahiro Inaba, Ryunosuke Nakagawa, Taiki Kamijima, Tomoyuki Makino, Renato Naito, Hiroshi Yaegashi, Kazuyoshi Shigehara, Takahiro Nohara, Yasutaka Yamada, Tatsuta Shimomura, Kenta Onishi, Atsushi Mizokami
Zitieren
APA
Iwamoto, H., Izumi, K., Hori, T., Inaba, T., Nakagawa, R., Kamijima, T., Makino, T., Naito, R., Yaegashi, H., Shigehara, K., Nohara, T., Yamada, Y., Shimomura, T., Onishi, K., & Mizokami, A. (2026). Survival Benefit of ARSI Therapy in Japanese mCSPC : A Systematic Review and Meta‐Analysis. International Journal of Urology, 33(8). https://doi.org/10.1111/iju.70603
Vancouver
Iwamoto H, Izumi K, Hori T, Inaba T, Nakagawa R, Kamijima T, et al. Survival Benefit of ARSI Therapy in Japanese mCSPC : A Systematic Review and Meta‐Analysis. International Journal of Urology. 2026;33(8). doi:10.1111/iju.70603
BibTeX
@article{Iwamoto2026,
author = {Iwamoto, Hiroaki and Izumi, Kouji and Hori, Tomohiro and Inaba, Takahiro and Nakagawa, Ryunosuke and Kamijima, Taiki and Makino, Tomoyuki and Naito, Renato and Yaegashi, Hiroshi and Shigehara, Kazuyoshi and Nohara, Takahiro and Yamada, Yasutaka and Shimomura, Tatsuta and Onishi, Kenta and Mizokami, Atsushi},
title = {Survival Benefit of ARSI Therapy in Japanese mCSPC : A Systematic Review and Meta‐Analysis},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {8},
doi = {10.1111/iju.70603}
}
EUVIMED